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SUMMARY
The World Health Organization estimates that globally 2.4 million people are
diagnosed with epilepsy each year. In nearly 30% of these cases, epilepsy cannot be
properly controlled by antiepileptic drugs. More importantly, treatments to pre-
vent or modify epileptogenesis do not exist. Therefore, novel therapies are
urgently needed. In this respect, it is important to identify which patients will
develop epilepsy and which individually tailored treatment is needed. However,
currently, we have no tools to identify the patients at risk, and diagnosis of epilep-
togenesis remains as a major unmet medical need, which relates to lack of diag-
nostic biomarkers for epileptogenesis. As the epileptogenic process in humans is
typically slow, the use of animal models is justified to speed up biomarker discov-
ery. We aim to summarize recommendations for molecular biomarker research
and propose a standardized procedure for biomarker discovery in rat models of
epileptogenesis. The potential of many phylogenetically conserved circulating non-
coding small RNAs, including microRNAs (miRNAs), as biomarkers has been
explored in various brain diseases, including epilepsy. Recent studies show the fea-
sibility of detecting miRNAs in blood in both experimental models and human epi-
lepsy. However, the analysis of circulating miRNAs in rodent models is challenging,
which relates both to the lack of standardized sampling protocols and to analysis
of miRNAs. We will discuss the issues critical for preclinical plasma biomarker dis-
covery, such as documentation, blood and brain tissue sampling and collection,
plasma separation and storage, RNA extraction, quality control, and RNA detec-
tion. We propose a protocol for standardization of procedures for discovery of cir-
culating miRNA biomarkers in rat models of epileptogenesis. Ultimately, we hope
that the preclinical standardization will facilitate clinical biomarker discovery for
epileptogenesis in man.
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CRITICALREVIEWAND INVITEDCOMMENTARY
A biomarker is a biological characteristic that is objec-
tively measured and evaluated as an indicator of normal bio-
logical or pathological processes, or a response to a
therapeutic intervention.1 An “ideal” biomarker should be
specific, sensitive, reproducible, predictive, and accurate.
The detection assay should be noninvasive, robust, stan-
dardized, affordable, and easy to perform.
Only a decade ago, microRNAs (miRNAs) were discov-
ered in mammals as a large class of evolutionarily con-
served small noncoding RNAs.2 miRNAs regulate gene
expression at the posttranscriptional level and, by influenc-
ing protein translation, they can be powerful regulators of a
wide range of biological processes. miRNAs have been
recently shown to regulate several key processes involved in
the development of epilepsy after brain injury in experimen-
tal models and humans.3 miRNAs are found in stable forms
in the circulating blood, where their levels change in disease
states, thereby representing an appealing source of mole-
cules that could serve as biomarkers for diagnosing or pre-
dicting the evolution of diseases, for example, the likelihood
of an epileptogenic process and the response to therapy.4
One of the major challenges in biomarker analysis of cen-
tral nervous system diseases is a reliable identification of
biomarkers that can be analyzed routinely in easily accessi-
ble samples such as blood. Recent studies show the feasibil-
ity of determining changes of circulating miRNAs in rodent
models of diseases, including brain diseases (Table S1).
However, comparison of data is challenging, as the method-
ologies used vary from study to study. For example, proto-
cols for blood sampling, plasma separation, and
quantitation of circulating miRNA levels vary. Preanalyti-
cal and technical factors can easily affect the miRNA levels,
resulting in bias that does not reflect the biological state of
the samples.5 Therefore, attention to methodological details
is critical.
The first step in setting up a pipeline for blood biomarker
discovery is to obtain high-quality blood samples (Fig. 1).
Standardized sampling protocols have been recommended
for human studies, which can be easily adopted in different
laboratories in multicenter trials (e.g., https://intbir.nih.gov/
sites/all/themes/nivea//NINDS_Repository_Biomarkers_
Discovery_Samples_Resource_Manual.pdf). The need for
powered, harmonized studies has been well recognized also
in experimental modeling of human diseases, including
biomarker discovery in epilepsy.6–8 Here, our objectives
were to (1) review the existing literature of plasma sam-
pling protocols in rat and (2) test and compare different
plasma sampling protocols, to identify the one that best
suits the needs of the search of miRNA biomarkers for
epileptogenesis.
Documentation
There are a number of factors that may influence the
expression of blood biomarkers (e.g., age, sex, strain, diet,
food and water intake, overall health, time of the day of
blood withdrawal, stress) that cannot be accounted for
without proper prospective documentation. The need for
standardization of preclinical studies was recognized in
the European Union 7th Framework–funded project Tar-
gets and Biomarkers for Antiepileptogenesis (EPITAR-
GET), a consortium of 18 partners in nine European
Countries, 12 of which conduct preclinical studies. This
led to the design of the first available common data ele-
ments (CDEs) for preclinical studies on epilepsy to help
investigators to systematically collect, analyze, standard-
ize, and share preclinical epilepsy data.8 These CDEs and
case report forms can be downloaded from the EPITAR-
GET Web page (www.epitarget.eu) and are highly recom-
mended. The work is being expanded to a wider spectrum
of epilepsy models by an International League Against
Epilepsy working group.9
Blood Sampling Techniques
Sampling from the lateral tail vein is quick and simple to
perform and can be performed repeatedly within the same
animal (see https://www.nc3rs.org.uk/rat-tail-vein-non-sur
gical). This technique requires the tail to be warmed (e.g., in
warm water) to dilate the lateral tail vein prior to taking the
sample. Typically, a 23-G needle or butterfly needle is used
to collect blood under short isoflurane anesthesia (induc-
tion, 5 vol%; maintenance, 1–2 vol%).
Other blood sampling techniques have disadvantages,
and therefore, are not preferred for blood
biomarker research (https://www.nc3rs.org.uk/rat-decision-
tree-blood-sampling). For example, blood vessel cannula-
tion requires surgery, and the indwelling tubes may affect
blood biomarker levels. Sampling from the jugular vein
requires a high degree of competence to avoid moderate or
significant harm to the animal. Sampling from the saphe-
nous vein is limited to a small volume (up to 200 lL).
Retro-orbital puncture, trunk blood collection, and intracar-
diac blood sampling should typically be performed as termi-
nal procedures and cannot be performed longitudinally
within the same animal. In addition, samples may be mixed
with other tissue fluids in trunk blood collection. One needs
to consider that biomarkers may be different in samples
from different cannulation sites.
Key Points
• We discuss the issues critical for preclinical plasma
biomarker discovery
• We propose a protocol for standardization of proce-
dures for discovery of circulating microRNA biomark-
ers in rat models of epileptogenesis
• We aim to facilitate clinical biomarker discovery for
epileptogenesis in man by preclinical standardization
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Figure 1.
Plasma biomarker discovery pipeline for epileptogenesis. The first step is set up methodologies for high-quality plasma sampling and
miRNA analysis as discussed in the text. Phase 1—biomarker discovery. In the discovery phase, miRNA sequencing from animals with struc-
tural epileptogenic lesions provides tens (or hundreds) of regulated miRNAs as compared to the control group. Bioinformatic analysis
reveals their target molecular networks as well as their presence in human miRNome. Phase 2—candidate biomarker identification. In vitro
validation of candidate miRNAs in rat plasma can be done, for example, using real-time polymerase chain reaction (RT-PCR) or droplet
digital PCR (ddPCR). One can also assess whether the top candidates are expressed in the brain of the same animal at a given time point.
Based on these analyses, the top candidates (about 10) will selected for further analysis. Phase 3—biomarker experimental validation. Levels
of top candidate miRNAs will be measured during epileptogenesis in plasma of animals, which are epilepsy-phenotyped with video-elec-
troencephalographic monitoring. Analysis can include several time points and several experimental models of epileptogenesis. Phase 3
can include assay development and optimization. Data analysis includes the definition of biomarker sensitivity and specificity, and determi-
nation of miRNA levels, which report on high risk of epileptogenesis. Phase 4—biomarker experimental qualification. Performance of candi-
date biomarker(s) to diagnose epileptogenesis should be demonstrated in an independent animal cohort using a statistically powered
study design. Phase 5—Clinical adoption. Preferably, the etiology of epilepsy in the study population should be comparable to that used in
experimental biomarker discovery. Human plasma should be collected in a standardized way, assay methodology should be adapted to
human samples, and “normal versus abnormal” levels of a given miRNA in human plasma should be determined. If validation is successful,
biomarkers should be taken to the regulatory approval process and commercialization. Phase 6. Eventually, miRNA biomarkers can
become part of clinical diagnostic assessment guidelines. miRNA biomarkers can also be used in preclinical and clinical therapy discovery
studies. BM, biomarkers; miR-seq, miRNA sequencing.
Epilepsia ILAE
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Blood Volume
Because the blood volume that can be withdrawn from
mice is quite small (50–200 lL), rats are more commonly
used for biomarker research (Table S1). A search in
PubMed using the terms “microRNA,” “biomarker,”
“blood,” and “mouse” revealed only four studies in which
miRNA biomarkers were studied for diseases of the central
nervous system using mice. For rats, the maximum volume
of blood that can be obtained on any single occasion is
<10% of the total blood volume (~2.56 mL in a 400-g rat)
and <15% of the total blood volume (~3.84 mL) in 28 days.
See https://www.nc3rs.org.uk/rat-decision-tree-blood-sa
mpling for more details.
Collection Tubes
Depending on the type of biomarkers and methods used,
plasma and/or serum can be obtained. Plasma is the cell-free
supernatant that is obtained after centrifugation of blood
that has been collected in the presence of an anticoagulant.
Serum is the cell-free supernatant obtained after centrifuga-
tion of blood that has been collected in the absence of an
anticoagulant and allowed to spontaneously clot. The essen-
tial difference between plasma and serum is the presence or
absence of fibrinogen and clotting factors, respectively. For
small noncoding RNAs (including miRNAs), plasma is pre-
ferred over serum to avoid (1) procedural variation in clot-
ting and coagulation process and (2) release of small RNAs
from blood cells (platelets, white and red blood cells) into
serum during the coagulation process.10,11
The type of anticoagulant used in plasma collection tubes
is also important to consider. Whereas K2 ethylenedi-
aminetetraacetic acid (EDTA) is an acceptable anticoagu-
lant for downstream analysis using quantitative polymerase
chain reaction (PCR), the use of heparin or trisodium citrate
as an anticoagulant potently inhibits subsequent PCR.11,12
The use of tubes containing EDTA in dried format is pre-
ferred over those containing EDTA in solution, because if
tubes containing a standard volume of EDTA are filled
incompletely, the final biomarker concentration is diluted
unequally as compared to other samples. Blood and EDTA
are mixed by inverting the tube 10 9 180° and back.
Centrifugation
After withdrawal of blood, plasma is separated using cen-
trifugation. Plasma has to be removed with caution to avoid
disruption of the buffy coat. Because plasma processing
conditions substantially influence circulating biomarker
levels,13 we recommend cooling the collected blood imme-
diately at 4°C and centrifuging it within 1 h to remove the
bulk of platelets at 1,300 9 g for 10 min at 4°C. At this
speed, most platelets will be removed, because much lower
centrifugation speeds (e.g., 600 9 g) are used to obtain
platelets.13 This is important, as platelets have a large reper-
toire of miRNAs and are the major source of miRNAs
in plasma,14 which can influence miRNA assessment.
However, plasma may still contain residual platelets,13,14
and therefore, we recommend a second centrifugation
(30009 g, 10 min at 4°C) to remove residual platelets.14,15
In case archived samples were frozen after the first centrifu-
gation step, the second step can be applied after thawing,
which effectively removes platelet contamination from
these samples.13 However, it should be noted that the
residual frozen platelets may have released miRNAs into
plasma.14
Although miRNAs in extracted plasma appear to be
stable at room temperature (at least up to 24 h), it is not yet
known whether the time interval between blood collection
and processing of plasma affects miRNA levels.12 Obvi-
ously, the optimal approach for miRNA purification from
the whole blood is to collect fresh blood and process the
sample as quickly as possible, and not later than 2–4 h after
collection.11
Storage
It has been reported that multiple freeze–thaw cycles
have no effect on reproducibility of miRNA profiling from
plasma.11,12 Nonetheless, it seems wise to avoid repeated
freeze–thaw cycles by freezing collected plasma immedi-
ately in smaller aliquots using dry ice and storing the sam-
ples at 70 to 80°C.12 Stability of blood miRNAs is due
to several protective mechanisms, including association
with plasma proteins, specifically argonaute-2 or lipopro-
teins, or encapsulation in extracellular vesicles.11 Extracted
miRNAs are very stable when stored at70°C for 1 year.16
Although specimens have been used that are several years
old, the effect of long-term storage on miRNA levels has
not yet been comprehensively evaluated. Thus, it is best to
match case and control specimens with respect to duration
of storage as much as possible.12
Plasma Quality Control
Poor plasma quality is typically caused by technical rea-
sons related to difficulties in blood withdrawal (e.g., dehy-
dration of animal, poor sampling technique/equipment) or
consequent plasma preparation in a given epilepsy model.
However, it is a striking observation that only 4% (two of
43) of published rat studies (Table S1) assessing miRNA in
rat plasma have used any quality measurements to assess
their sampling protocol performance.
There are several protocols that can be used for quality
control of rat plasma (Table 1). As discussed in the previous
paragraph, residual platelets that are present in plasma may
influence miRNA levels. Therefore, a proper quality control
for the presence of platelets should be performed. Similarly,
hemolyzed erythrocytes may also release miRNAs, which
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may lead to false discovery of disease-associated biomark-
ers.5,17–19 For human samples, Shah et al.18 have compared
several methods for detecting hemolysis in serum samples,
such as visual inspection, measurement of hemoglobin
absorbance by spectrophotometry at 414 nm, measurement
of hemoglobin using a Coulter AcT diff Analyzer, and the
ratio of red blood cell-enriched miR-451 to the reference
miR-23a. They reported that the miRNA ratio was the most
sensitive indicator of hemolysis, and therefore, was recom-
mended.
An alternative method is to measure hemoglobin at
414 nm and use a cutoff absorbance value of 0.20–
0.25.18–20 Although not a typical problem in rat samples, it
should be noted that lipemia in plasma interferes with hemo-
globin absorbance, which may cause an increase in absor-
bance values, even in the absence of any hemoglobin-
related peak.21 By also measuring the plasma absorbance at
385 nm (as a lipemia indicator) it is possible to identify
hemolyzed samples, independent of lipemia.21
Blondal et al.5 suggested that a ΔCq value of >5 for the
miRNA ratio indicator (miR-23amiR-451) implies possi-
ble erythrocyte miRNA contamination, and a ΔCq of 7–8 or
more indicates a high risk of hemolysis in human samples.
According to our analysis, the reference values suggested
for human serum/plasma hemolysis appear to remain rele-
vant for rat plasma (Fig. 2A1). In addition, we were able to
extend previous findings by showing that hemolysis in the
sample could also indicate platelet contamination. The ratio
of platelet-enriched miR-425 to reference miRNA miR-23a
correlated with erythrocyte contamination due to hemolysis
(r = 0.599, p < 0.01, Fig. 2A2,B). Absorbance of hemoglo-
bin in some samples indicated values >0.25 (Fig. 2C), which
was set as an upper limit.18–20
Our results suggest that absorbance of hemoglobin is a
more sensitive method for rat plasma than the ratio of red
blood cell–enriched miR-451 to miR-23a. In addition, after
brief practical training, hemoglobin absorbance correlated
well with the visual inspection of the plasma color. Interest-
ingly, when samples were freeze–thawed and centrifuged
(3,000 9 g), the miR-425:miR-23a ratio highly correlated
with erythrocyte contamination due to hemolysis
(r = 0.599, p < 0.01, Fig. 2D,E). These data suggest that a
simple visual inspection accompanied with absorbance
measurement of hemoglobin could indicate the overall rat
plasma quality for miRNA studies when an upper limit for
absorbance is set to 0.25. When this upper limit was used for
plasma samples obtained at different time points after elec-
trically induced status epilepticus (1 day, 1 week, 3–
4 months; n = 5–6 for each time point), none of the samples
had to be excluded (unpublished observations).
Platelet contamination can confound the measurement of
extracellular miRNAs, especially in archived plasma, if
only one centrifugation at a relatively low speed is per-
formed. Further studies with more thorough analysis of
hemolysis and platelet markers, for example, using a
Table 1. Quality control for rat plasma
Purpose Description Sample amount, lL Instrument Cutoff value References
Hemolysis Visual inspection — — Red color 18,19
Hemolysis Absorbance of
hemoglobin at 414 nm
1.0 Nanodrop-1000 or similar 0.20–0.25 19,20
Hemolysis Ratio of red blood cell–
enrichedmiR-451 to the
reference miR-23a
50–200
(for RNA extraction)
Real-time PCR system
(Applied Biosystems) or similar
ΔCq = 5
5,18
Platelet
contamination
Ratio of platelet-enriched
miR-425 to the reference miR-23a
50–200
(for RNA extraction)
Real-time PCR system
(Applied Biosystems) or similar
ΔCq = 1 5
PCR, polymerase chain reaction.
Table 2. Protocol for circulating biomarkers from rat
plasma
Parameter Protocol
Blood collection Tail vein withdrawal
Anesthesia 2–5% isoflurane
Needle 23-G butterfly needle
(#367284, BD Vacutainer)
Tube BDMicrotainer, 0.5 mL (#365975)
Tube temperature
when sampling
Room temperature
Mixing 109 inverting 180° and back
Storage temperature
prior to centrifugation
4°C
Storage time prior to
centrifugation
Max 1 h
Centrifugation 1,3009 g, 10 min, 4°C
2nd centrifugation Preferably before freezing
3,0009 g, 10 min, 4°C
Storage temperature after
centrifugation
4°C
Storage time after
centrifugation
Max 1 h
Tube for aliquots Eppendorf Protein LoBind Tube,
0.5 mL (#022431064)
Freezing Dry ice
Long-term storage 70°C to80°C
Plasma quality control Hemoglobin A414-nm < 0.25
RNA extraction 50–200 lL plasma miRNeasy kit
RT-qPCR normalization Spike-in controls, endogenous controls
RT-qPCR, real-time quantitative polymerase chain reaction.
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combination of multiple methods (or miRNAs) with a larger
number of animals, is needed to replicate and validate these
findings.
RNA Extraction
An underappreciated variable that can affect miRNA
quantification is the volume of plasma used for small RNA
extraction.22 Therefore, it is recommended to optimize
plasma volume for accurate quantification; too little plasma
will have insufficient miRNA for quantification, and too
much plasma can increase the concentrations of endogenous
polymerase inhibitors (e.g., hemoglobin, lactoferrin, or
IgG).22 In one study, it was observed that 50 lL of human
serum or plasma improved detection of miRNA by PCR as
compared to 10 or 200 lL.23 Another study reported that
200 lL of human plasma was to be preferred over 250, 300,
or 500 lL.16 We therefore recommend using 50–200 lL of
rat plasma for RNA extraction.
Several other factors during RNA extraction may also
affect miRNA quantification. A recent study using cell
cultures and human plasma showed that miRNA recovery
was largely influenced by the isolation method and by the
amount of input material used.24 RNA extraction methods
can be roughly classified into three main groups: (1) phe-
nol-based techniques that rely on the use of organic sol-
vents, phase separation, and recovery of RNA by
precipitation; (2) combined phenol and column-based
techniques that utilize phenol and chloroform to separate
RNA from other constituents, and a column for RNA
adsorption; and (3) column-based techniques that use a
phenol-free lysis buffer and a column for RNA recov-
ery.24 These three techniques were evaluated by compar-
ing phenol-based (TRIzol LS; Thermo Fisher Scientific),
two column–based (miRCURY RNA Isolation and miR-
CURY biofluids kits; Exiqon), and combined phenol- and
column-based (miRNeasy Mini kit; Qiagen) RNA isola-
tion techniques.24 The miRCURY kit permitted isolation
of highly pure RNA, of better quality when compared to
miRNeasy and TRIzol LS; however, miRCURY columns
tended to be saturated by large RNA species when the
RNA input was increased, which dramatically affected the
recovery of miRNAs.24 Interestingly, despite the low pur-
ity of TRIzol LS–extracted RNA, this method outper-
formed the miRCURY kit when using high-input
material.24 Importantly, when using low-input material,
the miRNeasy kit permitted better miRNA detection when
compared to the miRCURY kit.24 The ability to recover
miRNAs from 100 and 200 lL of human plasma was
comparable between miRNeasy and miRCURY kits,
whereas the detection of miRNAs from 50 lL was better
achieved with miRNeasy. Sourvinou et al.16 showed that
the mirVana PARIS kit and miRNeasy Mini Kit produced
the highest yield of recovery for a spike-in miRNA com-
pared to TRIzol extraction in human plasma samples, with
the first kit also demonstrating better performance than
miRNeasy. However, these results were in contrast to
those obtained by Kroh et al.12 demonstrating that RNA
extraction with miRNeasy led to a two- to threefold
increase in RNA yield compared to mirVana in human
samples. In another study, TRIzol LS, mirVana PARIS,
and miRNeasy kits were compared using human sam-
ples.15 The mirVana kit and the miRNeasy kit performed
better than TRIzol extraction, due to the presence of
organic and phenolic contaminants in the TRIzol-
extracted RNA.15 The miRNeasy kit had more stable
RNA yields through different extraction days.15 Similarly,
Page et al.25 compared three different commercial kits for
RNA extraction using human samples and demonstrated
that the miRNeasy kit produced the best quantity and
quality of circulating miRNAs.
Adding an RNA carrier before RNA extraction may
improve quantity and purity of extracted RNA.15,24 How-
ever, added RNA carrier can mask the quantity of extracted
RNA and affect accuracy in quantification and quality anal-
ysis.15
RNAQuality Control
There is no straightforward method to determine the qual-
ity of miRNAs extracted from plasma. A high RNA integ-
rity number (RIN) would suggest contamination with
mRNA (and miRNA) derived from circulating cells. Typi-
cally, the concentration and quality of RNA obtained after
extraction is measured using a NanoDrop spectrophotome-
ter. Although this can be used to assess the presence of con-
taminants such as peptides, phenols, aromatic compounds,
or carbohydrates and proteins, these methods do not provide
sufficient information about the concentration and quality
after extraction of small noncoding RNAs from plasma, due
to the low concentration of miRNAs.15,21,24 Alternatively, a
Bioanalyzer (Agilent Technologies, Palo Alto, CA, U.S.A.),
which utilizes a highly sensitive, chip-based assay, could be
used to detect small amounts of RNA. However, it is very
difficult to differentiate miRNAs from all other types of
small RNAs or from possible fragments produced by
degraded mRNA transcripts. This may be improved by
using a Fragment Analyzer (Advanced Analytical Tech-
nologies, U.S.A.). However, not every laboratory is
equipped with this apparatus. Generally, a fixed volume of
input material rather than an equal quantity of RNA is rec-
ommended after extraction of small noncoding RNAs for
plasma.21
Detection of miRNAs and
Normalization
For rat plasma, so far, real-time PCR has been the most
common method to assess miRNA levels (80% of studies,
36 of 43, Table S1). Other platforms include the sequencing
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(4%, two of 43), microarray (7%, three of 45), and Firefly
(2%, one of 43) techniques. Three studies evaluated here
did not report the platform they used (7%, three of 43).
For optimal quantification of plasma miRNAs, it is
important to consider the whole workflow starting from
sample processing.26 Later decision steps highlight the
Figure 2.
Hemolysis and platelet contamination in rat plasma obtained by tail vein withdrawal and standardized plasma separation procedure. (A1)
Hemolysis contamination. Ratio of red blood cell–enriched miR-451a to the reference miRNA miR-23a in samples obtained at 7 days
(baseline) before traumatic brain injury (TBI) and at 2 days, 7 days, or 3 months post-TBI. The miR-451a:miR-23a ratio did not differ
between the time points, indicating reliable sampling (p > 0.05, Mann–Whitney U test). Each time point included three control and four
TBI rats (no difference between the groups, p > 0.05, Mann–Whitney U test). Importantly, all samples had a ΔCq value < 5. No visual
hemolysis (red color) was detected among the samples. (A2) Platelet contamination. A ratio of platelet-enriched miR-425 to the refer-
ence miRNAmiR-23a in the same samples as presented in A1 is shown. The miR-425:miR-23a ratio did not differ between the time points
or groups, indicating reliable sampling (p > 0.05, Mann–Whitney U test). Our data suggest that samples having DCq (miR-23amiR-425)
close to or above 0 have a high risk of platelet contamination. (B) Correlation between sample contamination by red blood cells and plate-
lets (r = 0.599, p < 0.01, Spearman rank). (C) Correlation between DCq (miR-23a  miR-451a) and absorbance of hemoglobin
(r = 0.538, p < 0.01, Spearman rank). Plasma (n = 26) was sampled at 7 days (baseline) prior TBI, and at 2 or 14 days post-TBI. No differ-
ence was observed in DCq (miR-23a  miR-451a) or absorbance of hemoglobin between the time points, indicating reliable sampling
(p > 0.05, Mann–Whitney U test). Each time point included both control and TBI rats (no difference between groups [p > 0.05], Mann–
Whitney U test). (D) Series of plasma samples investigated with visual inspection, using a spectrophotometer (414 nm), and real-time
quantitative polymerase chain reaction (RT-qPCR; miR-23a, miR-451a, and miR-425). First, samples (n = 6) were ordered by an experi-
enced researcher according the color from yellowish to the most red-colored sample. Then, hemoglobin absorbance was measured using
a spectrophotometer.With visual inspection, the researcher was able to indicate that samples #5 and #6 were hemolyzed. Spectrophoto-
metric A414-nm analysis suggested that the fourth sample also had a significant hemoglobin content (>0.25). On the other hand, RT-qPCR
indicated that only the sixth sample was hemolyzed, according the guidelines for human samples (DCq [miR-23amiR-451a] > 5). In light
of these data, we suggest that visual inspection accompanied with spectrophotometric (A414-nm) measurement of hemoglobin is the best
approach to assess hemolysis in plasma samples from rat tail vein blood. Importantly, the hemolysis measurement indicated the overall
sample quality, as we found a relationship between the absorbance of hemoglobin with miR-451a (indicator of red blood cells) and with
miR-425 (indicator of platelets). (E1–E3). Correlations between the measured parameters in panel D. Hemoglobin absorbance was posi-
tively correlated with miR-425 content (platelet marker) in the sample (E1; r = 0.928, p < 0.01, Spearman rank). Furthermore, the level
of erythrocyte marker miR-451a was positively correlated with mir-425 content (E2; r = 0.812, p < 0.05, Spearman rank). In addition,
we observed a trend for a correlation between the ratio of red blood cell–enriched miR-451 to the reference miR-23a and hemoglobin
absorbance (E3; r = 0.771, p = 0.072, Spearman rank). Dotted lines represent the cutoff values suggested for human samples (see text
for references). Red data points indicate the samples with hemolysis in visual inspection (fifth and sixth) in panel D. Ab, absorbance of
hemoglobin; H, contamination by red blood cells; P, contamination by platelets; r, Spearman correlation coefficient; DCq, delta quantifica-
tion cycle; *p<0.05; **p<0.01
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importance of reduction of technical variation and choice of
PCR primers27 to be able to minimize the need of down-
stream normalization procedures. For rats, the most popular
reverse transcriptase and PCR system is usage of stem-loop
miRNA-specific reverse transcription oligonucleotides and
PCR probes (56% of all PCR studies). For quantitative PCR
normalization, plasma biomarker studies have used multiple
strategies (Table S1), and normalization after PCR is still
heavily used in comparison to efforts to minimize technical
variation prior to PCR. Overall, the most common method
is relative quantification normalized to external spike-in
(58%, 21 of 36; e.g., cel-miR-39, cel-miR-2, ath-miR159a).
Other methods are normalization to U6 or one or multiple
stable endogenous miRNA(s), normalization using global
mean normalization, or absolute quantification with syn-
thetic miRNA standard curve (which could be recom-
mended for real-time PCR if efforts to minimize technical
variability are performed). It is recommended to use a set of
spike-in templates during RNA isolation combined with a
carefully selected set of assays targeting endogenous miR-
NAs.5 Because PCR efficiency and normalization method
can have a massive impact on final real-time PCR results,
efforts to minimize technical variation and creation of intra-
and interassay controls as well as usage of digital PCR for
absolute quantification could have promise when develop-
ing miRNA biomarker platforms using rat plasma.
Next Generation Sequencing
Over the past decade, the development of various next
generation sequencing techniques has revolutionized
research in molecular genomics and transcriptomics. One
such sequencing technique known as RNA sequencing
(RNA-Seq), has surpassed microarrays as the gold-standard
for gene-expression studies.28 Unlike microarrays, which
use probe hybridization technology to quantify gene expres-
sion over a series of predefined probes, RNA-Seq produces
a digital signal from a cDNA library input. Apart from quan-
tifying gene expression levels and detecting differentially
expressed genes, RNA-Seq can also be used to explore alter-
native splicing events, detect novel transcripts, discover
gene fusion events, map transcription start sites, and iden-
tify sequence variation in transcribed regions.28–30 RNA-
Seq also has a lower level of background noise, can detect
low-abundance transcripts, and requires a lower concentra-
tion of input RNA than microarrays.28,29 RNA-Seq has been
utilized to successfully detect miRNAs and other small
RNAs in rat (unpublished data), bovine, and human
plasma.31–34
In most cases, library preparation of the extracted RNA
and the subsequent sequencing are completed at a commer-
cial sequencing facility in accordance to their in-house pro-
tocols. To reduce the possibility of the introduction of any
technical variation during these steps, experimental design
should be discussed with the sequencing facility prior to the
initiation of the project. Previously, when performing small
RNA-Seq on RNA extracted from serum, we have utilized
the Illumina TruSeq small RNA-Seq sample preparation kit
(Illumina, San Diego, CA, U.S.A.). This method of library
preparation will capture miRNAs, other small RNA species,
and novel small RNAs. Although sequencing itself is a
rather trivial process, it is known that lane and flow cell
biases exist during sequencing.35 Thus, it is important to
make sure that samples are pooled and/or split across lanes,
and when possible, all sequenced on the same flow cell. Fur-
thermore, sequencing facilities will generally not randomize
sample order and will simply process the samples in the
order received. Hence, randomization of sample order prior
to collection by the sequencing facility is paramount. It is
important to note here that any biases introduced during the
RNA isolation or library preparation stage will be enriched
during the sequencing process.36 For gene expression stud-
ies of moderately to highly expressed miRNAs as little as
1–2 million reads, single reads per sample may be suffi-
cient; however, for the detection of lowly expressed miR-
NAs, novel short RNAs, other RNA species, and isomiRs, a
much greater read depth is required (e.g., 12 million reads).
Bioinformatics Analysis of Rat
Plasma miRNA Data
Although RNA-Seq is widely utilized throughout the sci-
entific research community, no optimal data analysis pipe-
line exists. This is further confounded by the existence of a
large body of literature outlining different workflows or
analysis techniques each purporting to offer a superior,
more “true” representation of the transcriptome. In reality,
there is no one optimal method for the generation and analy-
sis of RNA-Seq data, and the techniques utilized are often
dependent on the biological questions being asked and the
personal preference of the bioinformatician analyzing the
data (for reviews and comparisons please see Conesa
et al.,37 Buschmann et al.,38 and Soneson and Delorenzi39).
The standard RNA-Seq data analysis workflow consists
of quality control, mapping of reads, quantification of genes
or transcripts, and differential expression testing, followed
by pathway or gene ontology enrichment analysis. As part
of good experimental design, the type of analysis should be
decided before the samples are sent for sequencing. A basic
work flow to identify differentially expressed genes is as
follows: (1) mapping of reads to the organism reference
genome using STAR, Bowtie2, or Burrow-Wheeler
Aligner; (2) quantification of reads that map to the location
of each miRNA or other short RNA species through Fea-
tureCounts or htseq-count; and (3) differential expression
testing using EdgeR or DESeq2 to identify genes of interest.
More advanced analysis methods such as various machine-
learning techniques40,41 can also be taken advantage of to
identify genes or transcripts of interest for further investiga-
tion. It is essential that selected miRNAs of interest are
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validated using a secondary technique such as real-time or
digital PCR.
Comparing miRNAs in Brain
Tissue and Plasma during
Epileptogenesis
The great advantage of using animal models of epilepto-
genesis is the availability of brain tissue for analysis. To
determine how changes in circulating miRNAs compare
with the changes in the brain, one has to determine their
expression in plasma as well as in the brain. Moreover, one
needs to assess the possible contribution of peripheral
organs to plasma miRNA levels during epileptogenesis. In a
recent study, we showed that the expression of miR-21 in
plasma reflects changes in the hippocampus and parahip-
pocampal cortex during epileptogenesis in the electrical
post–status epilepticus rat model.42 However, the pattern of
expression of miR-146a and miR-142 in plasma was differ-
ent from brain. miR-146a showed a tendency toward
increased expression during the chronic phase in plasma,
whereas in hippocampal subregions it was increased during
the latent phase. miR-142 showed increased expression in
plasma during the acute phase, but its expression was
increased in brain during the latent phase.42 In another
recent study, the expression of miRNAs in plasma and hip-
pocampal granule cells was investigated during epileptoge-
nesis after pilocarpine-induced status epilepticus in rats.43
Although 27 miRNAs were differentially expressed in
plasma, the only miRNA dysregulated both in plasma and
brain was miR-142. However, miR-142 was down-regulated
during the chronic phase and up-regulated during the latent
phase in granule cells.43 In contrast, Hu et al.44 showed that
the expression profile of miR-21, miR-22, miR-34a, and
miR-125a was similar in blood and hippocampus after pilo-
carpine-induced status epilepticus. Also during the acute
phase after kainic acid–induced status epilepticus, the
expression patterns of several miRNAswere similar between
blood and brain (e.g., up-regulation of miR-298 and
down-regulation of miR-155, miR-29c, miR-34b, miR-98,
miR-122, miR-155, miR-203, and miR-450a).45
Because the method used for processing brain tissue may
influence expression of (small) RNAs, we assessed RNA
and miRNA quality after sampling rat brain tissue using two
preservation methods: AllProtect tissue reagent (Qiagen)
and snap-freezing in liquid nitrogen (Fig. 3). We also
assessed the effect of time delay between decapitation and
sample preservation (5, 10, and 30 min before preservation,
n = 7 for each time point) on sample quality. Briefly,
macromolecules were isolated from the cerebral cortex
using AllPrep DNA/RNA/Protein Mini kit (Qiagen, Cat
No./ID: 80004) according to the manufacturer’s instructions
with few exceptions. To remove excess lipids, 20 mg PHM-
L LIPOSORB Absorbent (Millipore) was added before lysis
with TissueLyzer. The reagent was removed by centrifuga-
tion. Small RNA was collected from the protein fraction
with additional protocol using RNeasy MinElute cleanup
kit (Qiagen, Cat No./ID: 74204). The extraction was made
in five batches.
Total RNA quality
The RIN is a commonly used way to assess the integrity
of RNA in brain based on the ratio of 28S and 18S ribosomal
RNA.46 An acceptable RIN cutoff for downstream assays is
controversial, but in general RIN > 8 is considered to indi-
cate high-quality RNA.47,48 Furthermore, Illumina recom-
mends using RIN ≥ 8 for sequencing samples.
Analysis of total RNA quality (RIN, Agilent Bioanalyzer
RNA 6000 Nano Kit) indicated that samples preserved with
snap-freezing had a 0.54 U higher mean and 0.6 U higher
median RIN number as compared to samples preserved with
AllProtect reagent (Fig. 3A). The median RIN value was
0.35 U lower in the 30-min group than in the 5- or 10-min
groups, although the difference was not significant
(Fig. 3B). Although we did not detect any major effect of
delay between decapitation and tissue preservation on RIN,
all snap-frozen RNA samples from 5- to 10-min time points
had RIN > 8. However, in the 30-min batch a few samples
had RIN < 8. When AllProtect reagent was used, several
samples at all time points had RIN < 8, indicating lower-
quality RNA.
miRNA yield
Using lab-on-chip technology, it is possible to quantify
miRNAs as a percentage of small RNAs. The miRNA/small
RNA ratio is negatively correlated with RIN values, and can
be used to estimate the miRNA yield.49 Analysis of the
miRNA yield (using the Agilent Bioanalyzer 2100 Small
RNA kit) indicated that snap-frozen samples had a lower
(i.e., better) mean miRNA/small RNA ratio (Fig. 3D). The
miRNA/small RNA ratio increased when the preservation
was delayed from 5 to 10 min. However, there was no con-
sistent progression in the increase in miRNA/small RNA
ratio when the delay was prolonged to 30 min (Fig. 3E).
Analysis of day-to-day variability between the purification
batches indicated a higher miRNA/small RNA ratio in day 5
extraction as compared to others (Fig. 3F). The 5-day purifi-
cation batch included only 10-min samples, which might
partly explain the higher miRNA/small RNA ratio.
Like the total RNA quality justified by using the RIN, the
miRNA yield justified by using the miRNA/small RNA
ratio was also superior in snap-frozen samples as compared
to those preserved using AllProtect reagent. That purifica-
tion of miRNA is a delicate procedure was revealed by a dif-
ference in miRNA quality between extraction days
(Fig. 3F). It is also possible that use of separate extraction
procedures for purification of RNA and small RNAs con-
tributed to variability in miRNA/small RNA ratio.
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We recommend that rat brain tissue samples be preserved
with snap-freezing in liquid nitrogen within 10 min after
decapitation. The delay between decapitation and tissue
preservation should be monitored and reported. Our data
show that snap-freezing was a slightly better way to pre-
serve tissue samples, according to the RIN and the miRNA/
small RNA ratio.
Conclusions
Circulating small noncoding RNAs, particularly miR-
NAs, hold great promise as minimally invasive biomarkers.
Although there is growing attention to biomarker studies,
particularly in the preclinical field, there is a lack of consis-
tency and standardization. Therefore, we present a standard-
ization procedure to detect circulating miRNAs in rat
plasma (Table 2 and appendix). Once consensus procedures
have been defined and applied, studies conducted in
different laboratories can be expected to become more com-
parable, which will facilitate the identification and repro-
ducible use of biomarkers. Ultimately, this will lead to
novel diagnostic tests from easily assessable biofluids, such
as blood, and provide more insight into the disease mecha-
nisms, which is important for developing novel therapies for
the treatment of epileptogenesis in patients at risk.
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Figure 3.
Comparison of RNA quality obtained from brain samples using different preservation methods. Box plots of RNA integrity number (RIN)
for different (A) preservation methods, (B) time points, and (C) extraction days. Snap-freezing with liquid nitrogen is recommended over
AllProtect when 2-mm brain slices are sampled. Furthermore, our experiment suggested that the RNA quality is better when samples
were obtained within 10 min after decapitation. Boxplots of miRNA/small RNA ratio for (D) preservation method, (E) time points, and
(F) extraction days. Similarly, snap-freezing produced better quality of samples. In addition, one extraction day differed from others, indi-
cating possible complication in the purification process. *p < 0.05, **p < 0.01 calculated using Mann–Whitney U test.
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Appendix
Procedure for Circulating
Biomarkers from Rat Plasma
Tail vein withdrawal of blood
1 Anesthetize rat with isoflurane (5% induction, 1–2%
maintenance).
2 Warm up the tail with a heat lamp or in warm water to
dilate the blood vessels. Sampling site is the lateral tail
vein in the distal one-third of the tail. While extending the
tail, a 23-G butterfly needle (#367284, BD Vacutainer) is
inserted into the vein and blood is collected into a 0.5-mL
K2-EDTA tube (#365975, BD Microtainer, BD Bio-
sciences, Franklin Lakes, NJ).
3 Blood and EDTA are mixed by inverting the tube
10 9 180° and back.
4 The EDTA tube is placed on ice after mixing and kept for
a maximum of 1 h prior to centrifugation.
5 To separate plasma, centrifuge at 1,300 9 g, 10 min,
4°C.
6 Centrifuge at 3,000 9 g, 10 min, 4°C to remove residual
platelets, preferably before freezing.
7 The sample can be kept for a maximum of 1 h at 4°C.
Supernatant (plasma) is pipetted into Protein LoBind
tubes (#022431064, Eppendorf) and immediately frozen
on dry ice.
8 Samples are stored at70°C to80°C until processing.
Plasma quality control
1 Measure hemoglobin absorbance using a NanoDrop spec-
trophotometer (Thermo Scientific) at 414 nm using 1 lL
of plasma. The upper limit for absorbance is 0.25.
RNA extraction and quality control
1 Use 50–200 lL of plasma and extract small RNAs using
the miRNeasy kit (Qiagen) according to the manufac-
turer’s instructions. For real-time quantitative polymerase
chain reaction (RT-qPCR) normalization, add a (set of)
spike-in template(s), e.g., Cel-miR-39.
2 Determine miRNA quality using a Fragment Analyzer
(Advanced Analytical Technologies), or alternatively
using a Bioanalyzer (Agilent).
3 Use a fixed volume of input material, rather than an equal
quantity of RNA for RT-qPCR.
Normalization RT-qPCR
1 Use a (set of) spike-in template(s) during RNA isolation
combined with a carefully selected set of assays targeting
endogenous miRNAs.
Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Table S1. Summary of blood sampling protocols in stud-
ies using rat plasma for miRNA detection.
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